Marina Russo | Pharmacology, Toxicology and Pharmaceutical Science | Innovative Research Award

Innovative Research Award

Marina Russo
Luigi Vanvitelli, Italy

Marina Russo
Affiliation Luigi Vanvitelli
Country Italy
Scopus ID 59306460700
Documents 22
Citations 116
h-index 7
Subject Area Pharmacology, Toxicology and Pharmaceutical Science
Event International Award and Honors

The Innovative Research Award recognizes researchers whose scholarly activities contribute to the advancement of scientific knowledge and the development of innovative approaches within their respective disciplines. Marina Russo of Luigi Vanvitelli, Italy, has established a research profile focused on pharmacology, toxicology, molecular medicine, inflammation biology, and therapeutic innovation. Her publication record reflects sustained contributions to translational biomedical research, particularly in studies exploring inflammatory mechanisms, retinal disorders, metabolic disease complications, and novel therapeutic interventions.[1]

Abstract

Marina Russo’s research portfolio demonstrates active engagement in pharmaceutical sciences and translational biomedical investigations. Her studies address inflammatory pathways, neurovascular complications, diabetic disorders, ocular diseases, and innovative therapeutic strategies. Through interdisciplinary collaborations and peer-reviewed publications, she has contributed to expanding scientific understanding of disease mechanisms and potential pharmacological interventions.[2]

Keywords

Pharmacology, Toxicology, Pharmaceutical Sciences, Inflammation Research, Diabetic Retinopathy, Drug Delivery Systems, Molecular Medicine, Therapeutic Innovation.

Introduction

Scientific innovation in pharmaceutical and biomedical sciences requires a combination of experimental rigor, interdisciplinary collaboration, and translational relevance. Marina Russo has participated in research initiatives investigating inflammatory mediators, retinal degeneration, metabolic disorders, and therapeutic compounds. Her scholarly activities align with contemporary efforts to develop effective treatments for chronic diseases and inflammation-associated conditions.[3]

Research Profile

According to available scholarly metrics, Marina Russo has authored or co-authored 22 indexed publications, receiving 116 citations and attaining an h-index of 7. Her research activities are primarily associated with Pharmacology, Toxicology and Pharmaceutical Science, with emphasis on disease mechanisms, pharmacological modulation, ocular health, and translational medicine.[1]

Research Contributions

  • Investigation of lipid mediator biosynthesis inhibitors with potential anti-inflammatory applications.
  • Research on Vitamin D3 administration and protection against corneal damage in experimental disease models.
  • Exploration of galectin and purinergic receptor inhibition strategies in diabetic retinopathy.
  • Studies examining beta-hydroxybutyrate effects on retinal neurobiology and autophagy pathways.
  • Development of innovative drug delivery systems targeting diabetic cardiovascular complications.

Publications

  1. Potenza M, Giordano A, Chini MG, Saviano A, Kretzer C, Raucci F, Russo M, et al. Identification of 2-Aminoacyl-1,3,4-thiadiazoles as Prostaglandin E2 and Leukotriene Biosynthesis Inhibitors. ACS Medicinal Chemistry Letters, 2022.
  2. Trotta MC et al. Oral Administration of Vitamin D3 Prevents Corneal Damage in a Knock-Out Mouse Model of Sjögren’s Syndrome. Biomedicines, 2023.
  3. Lepre CC, Russo M et al. Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in Diabetic Retinopathy. IJMS, 2023.
  4. Trotta MC et al. Systemic Beta-Hydroxybutyrate Affects BDNF and Autophagy in the Retina of Diabetic Mice. IJMS, 2023.
  5. Trotta MC et al. Chrysin-Based Supramolecular Cyclodextrin-Calixarene Drug Delivery System. Frontiers in Pharmacology, 2023.

Research Impact

The impact of Russo’s research is reflected through scholarly citations, collaborative publications, and contributions to emerging therapeutic approaches. Her work has supported broader scientific discussions concerning inflammatory diseases, ocular pathology, metabolic complications, and pharmaceutical innovation. These contributions strengthen the evidence base for future translational and clinical investigations.[4]

Award Suitability

Marina Russo’s research profile demonstrates characteristics commonly associated with innovative scientific achievement, including interdisciplinary collaboration, publication productivity, and engagement with clinically relevant biomedical challenges. Her contributions to pharmacological research and therapeutic development align with the objectives of the International Award and Honors program, which seeks to recognize meaningful advancements in research and innovation.[5]

Conclusion

Marina Russo has developed a growing academic profile within pharmaceutical sciences through contributions addressing inflammation, diabetic complications, retinal health, and therapeutic innovation. Her publication record, citation performance, and participation in multidisciplinary research initiatives support recognition through the Innovative Research Award and reflect ongoing engagement with contemporary biomedical challenges.

References

  1. Elsevier. (n.d.). Scopus author details: Marina Russo, Author ID 59306460700. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59306460700
  2. Potenza M et al. (2022). Identification of 2-Aminoacyl-1,3,4-thiadiazoles as Prostaglandin E2 and Leukotriene Biosynthesis Inhibitors. ACS Medicinal Chemistry Letters.
  3. Trotta MC et al. (2023). Oral Administration of Vitamin D3 Prevents Corneal Damage in a Knock-Out Mouse Model of Sjögren’s Syndrome. Biomedicines.
  4. Lepre CC, Russo M et al. (2023). Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in Diabetic Retinopathy. International Journal of Molecular Sciences.
  5. Trotta MC et al. (2023). Systemic Beta-Hydroxybutyrate Affects BDNF and Autophagy in the Retina of Diabetic Mice. International Journal of Molecular Sciences.
  6. International Award and Honors. (n.d.). Award program information and recognition criteria.
    awardandhonors.com

Bubin Xu | Pharmacology | Best Researcher Award

Dr. Bubin Xu | Pharmacology | Best Researcher Award 

Associate Professor, at Jiangxi Science and Technology Normal University, China.

Bubin Xu  is a distinguished chemist and pharmaceutical scientist based in China. With deep expertise in light‑emitting polymers, nonlinear optical materials, and hybrid organic–inorganic systems, he earned his Ph.D. at the University of Missouri–Kansas City under Dr. Zhonghua Peng. Over three decades, Xu has progressed from research scientist roles in China and the U.S. to leadership positions including Vice President, R&D Director, and President at prominent pharmaceutical firms. Since 2017, he’s served as an Associate Professor at Jiangxi Science and Technology Normal University’s School of Medicine while continuing to guide innovative pharmaceutical research. Xu holds multiple patents and numerous peer‑reviewed publications, spanning advanced materials to herbal medicine standardization, marking him as a recognized authority in his fields.

Professional Profile

Scopus

🎓 Education

Bubin Xu completed his Bachelor’s (1987–1991) and Master’s (1993–1996) degrees in Fine Chemical Technology at East China University of Science & Technology, focusing on benzotriazole-based UV‑absorbers under advisor Qi Guozhen. In 1999, he pursued a Ph.D. in Chemistry/Pharmaceutical Sciences at the University of Missouri–Kansas City (1999–2003), under Dr. Zhonghua Peng. His doctoral research centered on high‑performance light‑emitting polymers, nonlinear optical materials, self‑assembling molecular architectures, and organic–inorganic hybrid systems. This academic foundation equipped Xu with robust theoretical knowledge and practical methodologies in materials chemistry and photonic polymers—skills vital for his subsequent roles in both academic and industrial settings.

💼 Experience

Xu’s career comprises a blend of academic and industry leadership. Since January 2017, he has been an Associate Professor at Jiangxi Science and Technology Normal University School of Medicine. Parallel to his academic role, he’s led Jiangxi RV Pharmaceutical as President since July 2010. Earlier, from 2007–2010, he helmed Hangzhou Joye Pharmaceutical, and before that, held senior research and executive positions at Zhejiang Qiming, Zhebang, Xinchang, and Liming Pharmaceutical firms. Notably, from 2003–2005, he was Principal Scientist at IRIX Pharmaceutical in South Carolina, USA. This extensive experience demonstrates his capacity to guide R&D teams, manage strategic growth, and translate lab discoveries into pharmaceutical innovations.

🔬 Research Interest

Xu’s research spans multiple domains: designing light‑emitting and nonlinear optical polymers, developing organic–inorganic hybrid materials (especially polyoxometalate‑based systems), and self‑assembling architectures. Lately, his focus expanded to analytical chemistry in herbal medicine—including standardization and quality control of herbal preparations like 金钱草 and 山慈菇. He also investigates fluorescence probes for lipid droplets and methods to analyze bioactive compounds via HPLC. His multidisciplinary approach integrates polymer chemistry, photophysics, and pharmaceutical analytics, aiming to enhance materials science and herbal therapeutics.

🏆 Awards

Xu earned several awards during his graduate studies at UMKC: the Graduate Travel Award (2000), the Mr. & Mrs. Fong Wu Cheng Award (2001), the Chancellor’s Scholarship (2001–2002), and the Distinguished Thesis Scholarship (2002–2003). After returning to China, he received the Jiangxi Province Scientific and Technological Progress Third Award (2016) and the Yingtan Scientific and Technological Progress First Award (2016). These honors acknowledge both his early academic excellence and later impact in scientific innovation and regional technological development.

📚 Top Noted Publications

Xu has authored over 20 publications, reflecting his interdisciplinary work:

1. Tu Y., et al.

Title: Trends in small‑molecule probes for lipid droplets
Journal: TrAC – Trends in Analytical Chemistry
Year: 2025
Details:
A recent review summarizing advances in the design and application of small-molecule fluorescent probes for imaging and studying lipid droplets in cells. This paper highlights the chemical structures, targeting mechanisms, and analytical techniques to monitor lipid metabolism and related diseases.
Note: Specific volume, issue, and DOI are not yet publicly available as the paper is forthcoming.

2. Cai Fang, et al.

Title: Quality Standard Study of Jin Qian Cao Granules (金钱草颗粒剂的质量标准研究)
Journal: Journal of JSTNU (Journal of Jiangsu Teacher’s University)
Year: 2024
Details:
This article focuses on establishing quality control standards for Jin Qian Cao granules, a traditional Chinese herbal medicine. It discusses the methodology for chemical component identification, content determination, and quality evaluation to ensure consistency and safety of the granules.
Note: Volume and issue details are not available; no DOI found.

3. Zheng K., Xu B.*

Title: Qualitative and quantitative analysis for monitoring the fishy odor of anchovy oil
Journal: International Journal of Food Engineering
Year: 2024
Volume/Issue: Vol. 20, Issue 4, pages 279–289
DOI: 10.1515/ijfe-2023-0047
Summary:
This study presents analytical methods combining sensory evaluation and instrumental techniques to identify and quantify volatile compounds responsible for the fishy odor in anchovy oil. The work aims to improve quality monitoring and odor control during production and storage.

4. Kang J., Xu B., et al.

Title: Molecular and polymeric hybrids based on covalently linked polyoxometalates and conjugated polymers
Journal: Angewandte Chemie International Edition
Year: 2005
Volume/Issue: Vol. 44, Issue 42, pp. 6902–6905
DOI: 10.1002/anie.200501924
Summary:
This paper reports the synthesis and characterization of novel molecular and polymeric hybrid materials formed by covalently linking polyoxometalates to conjugated polymers. The hybrids show unique electronic and catalytic properties with potential applications in materials science and catalysis.

5. Xu B., Peng Z., et al.

Title: Synthesis and Optical Properties of Conjugated Polymers Incorporating Polyoxometalates
Journal: Chemistry of Materials
Year: 2005
Volume/Issue: Vol. 17, Issue 11, pages 2841–2851
DOI: 10.1021/cm050188r
Summary:
This research details the synthesis of conjugated polymers that incorporate polyoxometalates, exploring their photophysical and optical behaviors. The study offers insights into the design of advanced functional materials for optoelectronic applications.

6. Xu B., Peng Z., et al.

Title: Polyoxometalates covalently bonded with terpyridine ligands
Journal: Chemical Communications
Year: 2003
Issue: 20, pages 2562–2563
DOI: 10.1039/b307415c
Summary:
The paper describes the preparation of polyoxometalates functionalized with terpyridine ligands through covalent bonding. The hybrid compounds are studied for their structural and coordination properties, contributing to the field of inorganic-organic hybrid materials.

Conclusion 

Dr. Bubin Xu is a highly accomplished researcher with a diverse and sustained record of contributions to the fields of pharmaceutical sciences and materials chemistry. His blend of academic and industrial achievements, particularly in synthesis, analytical methods, and product development, makes him a strong candidate for a Best Researcher Award, especially at the regional or institutional level.